Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01
Entry into a Material Definitive Agreement.
Note and Common Stock Exchanges.
On November 13, 2026, SPAR Group, Inc., a Delaware corporation (the “Company”), and SPAR Marketing Force Inc., a wholly owned subsidiary of SPAR (“SPM”), entered into an Exchange Agreement (the “Exchange Agreement”) with ReposiTrak, Inc. (“TRAK”) and PC Group, Inc., a wholly owned subsidiary of TRAK (“PCG”). Pursuant to the Exchange Agreement, PCG agreed to exchange all outstanding principal and accrued interest under its promissory note receivable from SPAR (the “Note”), totaling approximately $4.0 million (the “Note Exchange”), for shares of the Company’s Series C Convertible Preferred Stock, par value $0.01 per share (the “Series C Preferred”), having a stated value of $1,000 per share (“Stated Value”). The Series C Preferred (i) is convertible into the Company’s common stock, par value $0.01 per share (the “Common Stock”), at $0.38 per share (“Conversion Price”), (ii) pays cumulative dividends at 8% per annum, payable quarterly in cash, with an additional 2% per annum if paid in additional shares of Series C Preferred, (iii) is senior to all other equity, equal to the Stated Value plus accrued but unpaid dividends, and (iv) votes together with the Common Stock on an as-converted basis, subject to the Beneficial Ownership Limitation, defined below. TRAK may also exchange other amounts due and owing it by the Company (“Future Obligations”), currently totaling approximately $1.1 million, for additional shares of Series C Preferred.
In addition, TRAK and PCG agreed to exchange their aggregate holdings of 8,900,406 shares of Common Stock for 3,360 shares of Series C Preferred, representing an agreed aggregate exchange value of $3,359,605 (the “Common Exchange” and, together with the Note Exchange, the “Exchanges”). As additional consideration for the Exchanges, the Company agreed to issue TRAK a single warrant to purchase an aggregate of 9,684,211 shares of Common Stock at an exercise price of $0.38 per share (the “Warrant”). Upon consummation of the Exchanges, the Note and the 8,900,406 shares of Common Stock were cancelled. The Warrants similarly have an exercise price equal to the Conversion Price and are exercisable beginning January 31, 2028 with a four-year term, expiring January 31, 2032.
The Series C Preferred and Warrants are subject to beneficial ownership limitations whereby they shall not be exercisable, and the Series C Preferred cannot be converted, to the extent their exercise or conversion, as the case may be, would cause the beneficial ownership of Common Stock held by TRAK to exceed 50% of the total issued and outstanding shares of Common Stock (“Beneficial Ownership Limitation”). The Beneficial Ownership Limitation expires on December 23, 2027, after which date TRAK’s beneficial ownership could exceed 50% upon conversion of Series C Preferred or exercise of the Warrants.
The Exchange Agreement also provides for TRAK to indemnify the Company and its officers and directors against any claims arising out of the Exchanges after the Company’s directors’ and officers’ insurance and charter indemnification have been exhausted.
Revolving Credit Agreement.
In connection with the Exchanges, TRAK entered into a Revolving Credit Agreement with the Company on November 13, 2026 (the “Credit Agreement”), providing for a revolving credit facility of up to $1.5 million (the “Line of Credit”). The Company may satisfy its commitment through direct advances, credit support for financing provided by third-party lenders, or a combination thereof, subject to the terms of the Credit Agreement. Outstanding direct advances bear interest at 8% per annum, payable monthly in cash, with an additional 2% per annum during the continuance of an event of default. The Line of Credit matures on November 13, 2028, subject to adjustment to the next business day (the “Maturity Date”).
At the Maturity Date or following acceleration of the outstanding balance, TRAK may, at its sole election, require repayment of outstanding principal in cash, convert all or a portion of such principal into Series C Preferred at its Stated Value, or elect a combination of cash repayment and conversion. the Company has no right to require or reject a conversion validly elected by TRAK. Accrued and unpaid interest remains payable in cash unless otherwise agreed in writing.
As additional consideration for the Line of Credit, the Company is obligated to issue warrants to TRAK in connection with qualifying direct advances, providing 50% warrant coverage based on the Conversion Price (the “Conversion Warrants”), regardless of whether the underlying principal is subsequently converted. The Conversion Warrants have an exercise price of $0.38 per share, are not exercisable before the later of January 31, 2028 and their issuance date, and have a four-year term commencing on that date.
The Credit Agreement also provides that, if TRAK arranges or procures qualifying third-party financing for the Company or its subsidiaries (“Sourced Financing”), TRAK will receive additional Series C Preferred (the “Sourcing Shares”) and warrants providing 50% coverage (the “Sourcing Warrants”). Such consideration is determined by reference to the qualifying financing commitment, subject to an aggregate $1.5 million limitation and provisions preventing duplicative warrant coverage. The Sourcing Shares and Sourcing Warrants are issuable in accordance with the Credit Agreement regardless of whether the third-party financing is fully drawn.
For so long as TRAK holds Series C Preferred, if the Company issues Common Stock or securities convertible into or exercisable for Common Stock, the Company must issue TRAK additional shares of Series C Preferred so that TRAK's as-converted percentage ownership of the Company remains unchanged. This protection also applies to issuances to TRAK, including Series C Preferred issued under the Credit Agreement, as dividends or in exchange for Future Obligations; Common Stock issued on conversion of the Series C Preferred or exercise of the Warrants; and the additional anti-dilution shares themselves.
The foregoing descriptions of the Exchange Agreement, Credit Agreement and form of Warrant do not purport to be complete and are qualified in their entirety by reference to the full text of the Exchange Agreement, Credit Agreement and form of Warrant filed as Exhibit 10.1, 10.2 and 10.3, respectively, to this Current Report on Form 8-K, and incorporated by reference herein.